Related Articles or Presentations
Urology Practice, retrospective chart review analysis of genomic assay used in men newly diagnosed with prostate cancer (November 2015; online July 2015) Abstract
World Journal of Urology, EU5 NMIBC treatment Abstract
The Journal of Urology, US NMIBC treatment Abstract
Society of Urologic Oncology and World Urologic Oncology Federation, concerns over quality of care in older patients, cancer study Presentation
ASCO, duration of CSF therapy Paper
We have conducted many studies of various cancer conditions and treatments, including studies of multiple myeloma, forms of leukemia, mCRC, melanoma, lung cancer, breast cancer, ovarian cancer, testicular cancer, and lymphomas including mantle cell and non-Hodgkins, as this chart reveals.
Results of some of these studies have been presented at ASCO and at other important medical conferences.
For more than 15 years we studied colony stimulating factor (CSF) use in patients with blood disorders and blood cancers including multiple myeloma and various forms of leukemia.
Prostate cancer was another key part of our CSF studies, and more recently we have studied genomic testing for prostate cancer.
We began studying HER2 as a breast cancer research variable in the early 1990s, conducting tracking studies that examined the extent to which physicians were recording breast cancer patients’ HER2 status.
Our experience includes multi-nation studies of non-muscle invasive bladder cancer (NMIBC), on which we published both in the US and in Europe with leading urological oncologists. (See links.)
Our studies of orchiectomy patients and the client’s implementation of our recommendation to sponsor support groups for testicular cancer patients brought the client an award from the American Urological Association.